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MCP-1 RELEASE MODULATION THROUGH INTERACTION OF PULMONARY
ENDOTHELIAL CELLS AND MESENCHYMAL STROMAL CELLS
Kaavya Giridhar, B.S.
Advisory Professor: Sean I. Savitz, M.D.
Background: Ischemic stroke is a leading cause of death and long-term disability
around the world. Current treatment options are limited to the administration of
tissue plasminogen activator (tPA) and/or endovascular therapy, administered within
a limited time window. However, cell-based therapies such as mesenchymal stromal
cells (MSCs) have increasingly shown great promise for ischemic stroke recovery
with some therapies already in various stages of clinical trials. Intravenous (IV)
administration of the MSCs leads to the entrapment of these MSCs in the lungs.
These entrapped MSCs interact with the pulmonary endothelial cells (PECs) and
could modulate the immune response through the release of cytokines and
chemokines. Monocyte Chemoattractant Protein - 1 (MCP-1), is an important
chemokine involved in the recruitment of monocytes and macrophages. In our study,
we wanted to explore the interactions between MSCs with PECs and how this
interaction changes the expression levels of MCP-1 and other cytokines after an
inflammatory event such as stroke. We also wanted to see if MCP-1 released
through the interaction between MSCs and PECs under inflammatory conditions,
modulates the immune response through the modification of monocytes.
Methods: Cultured murine PECs were grown either alone or in combination of
murine MSCs, and were exposed to 1) a combination of IFN-γ and TNF-α
inflammatory stimuli or 2) Anti MCP-1 antibody to neutralize any secreted MCP-1.
The secretome release of IL-1β, IL-1ra, IL-6, MCP-1, and VEGF were analyzed
vi

using ELISA (BD Biosciences and R&D Systems). To further understand the
immunomodulatory response, the collected media from the previous step was added
to splenic immune cells (CD11b+) and splenic monocytes (CD115+). The secretome
release was analyzed from these cells using ELISA.
Results: MCP-1 secretion levels were increased from PECs as well as co-cultures
of PECs and MSCs when they were exposed to inflammatory stimuli. When cocultures of PECs and MSCs were exposed to recombinant MCP-1 or MCP-1
neutralizing antibody, VEGF secretion levels decreased. In the presence of
inflammatory stimuli, co-cultures of PECs and MSCs secreted elevated levels of
VEGF. While under inflammation, we also observed that IL-6 levels were elevated
and they remain elevated even when MCP-1 was neutralized. We did not observe
any difference in secretome release from neither the splenic immune cells (CD11b+)
nor the splenic monocytes (CD115+).
Conclusion: Our data show that MCP-1 release under stroke like conditions is
modulated through the interaction of PECs and MSCs. However, our study was
unable to elucidate MCP-1’s role in the modification of monocytes.

vii
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CHAPTER 1: INTRODUCTION

1

1.1 Stroke
Stroke is a leading cause of death and long-term disability in the United
States and around the world. According to CDC reports, the cost burden in the US
brought on by stroke has been estimated to be around $34 billion per year towards
medications, health care services, and missed workdays 1. There are two major
types of strokes: ischemic and hemorrhagic stroke, where ischemic stroke
constitutes about 87% of all stroke cases 1, 2 . Research over the years has identified
many risk factors and have categorized them as non-modifiable, i.e., age, sex,
race/ethnicity, etc., and modifiable, i.e., hypertension, diet, physical activity,
smoking, etc., risk factors 3.

1.1.1 Ischemic Stroke Pathophysiology
The majority of the stroke cases comprises of ischemic stroke, especially
amongst the developed countries 3. Ischemic stroke is caused due to the occlusion
of the blood vessel(s) in the brain, which disrupts the supply of oxygen and glucose
to the affected regions in the brain

4, 5

. The infarct core is the central region affected

directly by the loss of blood flow, and the region surrounding this core is called the
ischemic penumbra, where there’s some residual perfusion present from the
neighboring vessels 6. The interruption of blood flow to these regions leads to
irreversible damage to the brain tissue through a series of events called the ischemic
cascade. The cellular and molecular events triggered by the cascade involve the
formation of reactive oxygen species, accrual of intracellular calcium, the release of
glutamate, mitochondrial damage, initiation of apoptosis and necrosis, excitotoxic

2

neuronal death, and induction of inflammatory processes both within the brain and
peripheral tissues 4, 7, 8.
The inflammatory process within the brain is initiated through the release of
damage-associated molecular pattern (DAMP) signaling released by the dying cells
in the infarct core and ischemic penumbra regions 6. Subsequently, these signals
lead to the production of pro-inflammatory cytokines and chemokines that triggers
the immune response cycle both centrally within the brain and peripherally through
the entire system 6. The immune response followed after stroke seems to be
emerging as a key player in the development of stroke severity and a good target to
obtain therapeutic benefits.

1.1.2 Current Stroke Treatments

1.1.2.1 tPA
Tissue plasminogen activator (tPA) is the only noninvasive treatment
approved by the Food and Drug Administration (FDA) for ischemic stroke in the US.
It is a factor that aids in the breakdown of blood clots that’s causing the occlusion
and restoring blood supply to the brain. The administration of tPA is, however,
restricted to a narrow time window within 4.5 hours after the onset of stroke
symptoms. This time constraint severely limits the number of patients who are
eligible to receive it as a treatment.

3

1.1.2.2 Endovascular Therapy
Endovascular therapy or mechanical thrombectomy is a recently added
standard of care treatment for ischemic stroke patients with large vessel occlusion.
The clot is removed using a stent retriever. The stent is inserted into the blocked
vessel; the stent then opens and grabs the clot for removal. The therapy can only be
performed on patients with large vessel occlusion within 24 hours of the onset of
acute stroke symptoms.

1.2 Cell Therapy
Cell-based therapies are another promising treatment option that has been
explored for ischemic stroke. The main focus of current ischemic stroke treatments
is to swiftly restore blood flow to the brain, to prevent any further damage. However,
cell-based therapies aim to improve and restore functional recovery in acute and
chronic stroke cases. Several pre-clinical animal studies have demonstrated over
the years that cell therapy can achieve functional recovery

9, 10, 11

. Studies have

looked at a variety of cell sources to be used as a therapy; including stem cell types
like bone-marrow derived mesenchymal stem/stromal cells (BM MSCs), bonemarrow derived mononuclear cells (BM MNCs), adipose-derived stem/stromal cells
(AD MSCs), neural stem cells (NSCs), embryonic stem cells (ESCs), umbilical cord
blood-derived stem cells, induced pluripotent stem cells (iPSCs), dental pulp derived
stem cells and precursor/progenitor cells like endothelial progenitor cells (EPCs),
neural precursor cells (NPCs) and multipotent adult progenitor cells (MAPCs)

12, 13

.

Pluripotent stem cells such as the ESCs and iPSCs have the potential to
differentiate into any cell type from the three germ layers with an ability to self renew
4

indefinitely

13-15

. The same property could lead them into forming tumors after

engraftment and are tagged with certain ethical concerns 13-15. Multipotent cells such
as MSCs, NSCs, EPCs, etc., on the other hand, have to potential to differentiate into
only certain types of specialized cells but have fewer health risks and ethical issues
attached to it 13.
Initially, cell therapy aimed to repair the tissue damage through the
recruitment of cells for tissue grafting to repair the infarct region

16

. However,

growing studies have demonstrated that engraftment was not a factor in seeing the
treatment effects; instead, the exogenous cells created an endogenous restorative
effect within the brain. It was observed that these cells modulated the changes by
providing trophic support and by modifying cell-signaling pathways that downstream
enhanced the endogenous restorative process by promoting neurogenesis,
angiogenesis, synaptogenesis, immune modulation, etc.,

9, 13, 16

. Such compelling

pre-clinical data has led to the testing of these cell-based therapies on human stroke
patients, with certain cell types reaching phase 3 of clinical trial testing. Table 1
gives a brief picture of different cell types that are currently or have been previously
under investigation for clinical stroke trials using data from ClinicalTrial.gov, Krause,
M. et al., 2019 and, Trounson, A. and McDonald, C., 2015 9, 17.
Cell Type
BM MSCs
BM MNCs
AD MSCs
Hematopoietic Stem Cells
NSCs
Umbilical Cord Blood

Routes of Administration
IA, IV, IN, IT
IA
IV, ICb,
IV
IC, ICb
IV

5

Clinical Trial Phase
Phase 1, 2, 3
Phase 1, 2
Phase 1, 2
Phase 1, 2
Phase 1, 2
Phase 1, 2

Table 1 Types of Cells Currently or Previously Under Clinical Stroke Trial
Investigations. IA – Intra-Arterial, IC – Intracranial, ICb – Intracerebral, IN –
Intranasal, IT – Intrathecal, IV – Intravenous.

1.2.1 MSC Therapy
Mesenchymal stem/stromal cells (MSCs) are one of the most widely studied
cell types as a cell-based therapeutic for stroke. MSCs, as mentioned previously, are
multipotent cells that can be easily isolated and expanded from different adult tissue
sources such as bone marrow, adipose tissue, umbilical cord blood, etc.,

13

.

According to the International Society for Cellular Therapy, MSCs are defined using
certain standards: it’s plastic adherence, the expression of CD90, CD73, CD105 and
the lack thereof CD45, human leukocyte antigen (HLA) Class II, CD11b, etc., and
the ability to be multipotent

18

. The lack of HLA Class II markers enables the MSCs

to have a relatively low or no immune reaction and also reduces the risk of immune
rejection when the cells are allogeneic

13, 18

. Intravenous (IV) administration of MSCs

is one of the safer routes of administration amongst patients, as it’s much less
invasive compared to other routes such as intracerebral (ICb) and intra-arterial (IA).
A growing number of studies have demonstrated that MSCs play an essential role in
facilitating neuroprotection, modulating the immune response by acting of various
immune cells, suppressing inflammation through the modulation of peripheral organs
such as lungs and spleen where MSCs get lodged after an IV administration, etc.,
19

8,

. Preclinical studies have also widely shown enhanced functional recovery in

animals following treatment with MSCs 20, 21.

6

1.2.2 Intravenous Administration and Pulmonary Passage
IV administration of MSCs has been studied in many preclinical and clinical
studies. A majority of the cells after an IV infusion get trapped in the lungs, which is
referred to as ‘pulmonary first-pass’ and only a small percentage reaching the
spleen, liver, and the actual ischemic brain penumbra

22-25

. Studies showed that

cultured MSCs overtime changed their morphology from small round shaped cells to
long spindle shaped cells and have an average diameter of 20 µm. The large cell
diameter made the MSCs too big to pass through the pulmonary microvasculature,
which usually ranged between 5-10 µm in diameter

23, 26, 27

. Cell surface adhesion

molecules expressed by MSCs and cells like endothelial cells were also later found
to be a reason for the entrapment by various studies 25, 28, 29. Initially, this entrapment
was considered to be a hindrance to the treatment effects of MSCs. However,
studies showed that despite a majority of the cells being trapped in the peripheral
organs such as the lungs, therapeutic effects were still observed

30

. The exact

mechanism behind this is still unknown, and many studies are pointing towards an
immunomodulatory role played by MSCs 8.

1.3 Immunomodulatory Role of MSCs
Over the years, a growing number of studies have suggested that MSCs play
a significant role in modulating the immune response after an inflammatory event
such as stroke. Exposure to an environment that is inflammatory can influence the
immunomodulatory function of the MSCs

31

. Studies have shown that exposure of

MSCs to inflammatory cytokines such as TNF-α and IL-1β augmented their
regenerative potential

32

. Other studies have shown that secretory factors such as
7

TSG-6, TGF-β, HGF, PGE-2 demonstrated a reduced inflammatory immune
response, which also includes inhibition of T-cell proliferation and promotion of
regulatory T-cells (Tregs) expression

30, 33-36

. Indoleamine 2,3-dioxygenase (IDO)

has also been identified as a factor secreted by the MSCs that play a role in the
generation of Tregs

27

. Studies have also shown that MSCs trapped in peripheral

organs such as the spleen and lungs interact with surrounding cell types such as
splenocytes or pulmonary endothelial cells to release various secretomes that have
systemic effects 8, 37.

1.4 Monocytes and Macrophages
Monocytes/macrophages are an important subset of immune cells, through
which MSCs carry out their immunomodulatory effects. Under inflammatory
conditions, monocytes/macrophages are driven towards the M1 type, a proinflammatory subset. Pro-inflammatory factors such as lipopolysaccharide (LPS),
TNF-α, and IFN-γ were shown to drive the cells towards the M1 phenotype. These
cells also produced more pro-inflammatory cytokines such as TNF-α, IL-1β, IL-12,
IL-23, and nitrogen monoxide (NO)

38

. MSCs have shown to favor the polarization of

monocytes/macrophages towards an M2 anti-inflammatory phenotype, while also
reducing the M1 type activity

35

. The M2 phenotype cells secreted anti-inflammatory

cytokines such as IL-10 and reduced pro-inflammatory cytokines such as TNF-α, IL12

39, 40

. Studies have also shown M2 phenotype monocyte/macrophages expressed

high levels of cytokines/chemokines such as IL-8, IL-6, MCP-1, EGF

41, 42

. The

immunomodulatory effect exerted by MSCs through their modulation of the

8

monocytes/macrophages could be a key factor in understanding their therapeutic
effects in disease conditions.

1.5 Monocyte Chemoattractant Protein – 1
Monocyte chemoattractant protein – 1 (MCP-1), a C-C family chemokine, is
primarily involved in the recruitment of monocytes/macrophages. Many cells,
including the endothelial cells, monocytes, macrophages, microglia, astrocytes,
neurons, etc., produce MCP-1. The role of MCP-1 has been mainly associated with
the migration and infiltration of the mononuclear cells, such as monocytes to areas
of inflammation and infection. Recent studies have also pointed out their critical
involvement in routine immune surveillance and immune modulation 43. Studies have
shown that MCP-1 activity is mediated primarily through C-C chemokine receptor 2
(CCR2)

43

. There are two isoforms of the receptor, CCR2A, and CCR2B, which

possibly activate different pathways and leading to different actions 43.

1.5.1 Role of MCP-1 in Pathologies Involving Neuro-inflammation
Extensive work has been done on the position of MCP-1, primarily being a proinflammatory molecule in various pathologies. Some of the widely studied disease
models linked to the role of MCP-1 include atherosclerosis, multiple sclerosis,
Alzheimer’s disease, rheumatoid arthritis, brain ischemia, HIV, etc.,

43, 44

. Many of

these diseases have an inflammatory component associated with them, and studies
have shown that MCP-1 directly mediates the recruitment of monocytes to the foci of
active inflammation

43,

45

. In Multiple Sclerosis (MS), a neuroinflammatory

demyelinating disease, the lesions have presented with the infiltration activated
9

macrophages and lymphocytes. Studies have shown elevated MCP-1 expression in
MS plaques

44

. This would indicate that MCP-1 plays a major role in the

inflammation progression in MS. Studies have also indicated that mice who lack the
CCR2 receptor have shown no signs of neuroinflammation
Alzheimer’s

disease

(AD),

another

neurodegenerative

44

. Studies on

disease,

have

also

increasingly shown that there is a possible involvement of the MCP-1/CCR2 axis in
the development of the pathology. Apart from its detrimental effects, MCP-1 has also
been implicated in studies to be involved in the clearance of senile plaques

44

.

Studies are slowly uncovering the fact that MCP-1 could have both positive and
negative roles in disease pathologies.

1.5.2 Role of MCP-1 in Ischemia
As mentioned earlier, inflammation plays a major in the progression and
outcome of ischemic injury. The main inflammatory event in post-ischemia is the
recruitment of leukocytes, neutrophils, and mononuclear cells like monocytes, which,
as mentioned before, are recruited through the actions of MCP-1
Arakelyan et al., 2005,

47

46

. In the study by

patients who suffered from ischemic stroke had about a 2-

fold increase in MCP-1 levels in their serum compared to the control groups 47. Other
animal studies have also indicated that animals, when void of MCP-1 has smaller
infarct volumes compared to that of control mice, post an ischemic event 48. While on
the other hand, studies have also shown that post-ischemia (hind-limb), local
infusion of MCP-1 protein, improved homing of monocytes and could also be
involved in the regulation of angiogenesis in the ischemic region 49.

10

1.5.3 Role of MCP-1 in Cell Therapy
The role of MCP-1 is seldom looked at in such therapeutic settings. Studies
have looked into the migration pattern of MSCs after extracts from brain tissue post
a middle cerebral artery occlusion (MCAo) versus controls. They noticed that MCP-1
levels influenced migration patterns of the MSC in these groups

50, 51

. A previous

study conducted by our group also has shown that autologous post-stroke
mononuclear cell (MNC) from rats when administered post an MCAo, the outcomes
were much better compared to the saline control group

11

. The infarct size was

significantly reduced in these animals compared to the saline control group while
also showing an enhanced recovery compared to the other groups

11

. One

significant point to be noted here is that serum levels of MCP-1 were increased in
animals treated with post-stroke MNCs compared to the other groups
al., 2011

52

11

. Andres et

demonstrated that intra-arterially delivered NSCs had better homing in

the ischemic region in animals with MCP-1 expression compared to the animals with
no MCP-1 expression 52. In another study, rats with spinal cord injuries when treated
with MCP-1/ED-Siglec-9 secreted by MSC derived from human deciduous dental
pulp showed improved hind-limb movement and also demonstrated the recruitment
of M2 type monocytes/macrophages to the region of injury

53

. The study also

showed that when the animals were treated with a combination of MCP-1/EDSiglec9 the treated animals had increased recruitment of M2 like cells, which was indicated
by the cell surface marker CD206, compared to the control group 53.
The function of MCP-1 is altered based on the situation they are presented,
and this is clear from the previously described studies. In disease condition, MCP-1
is primarily portrayed as being a molecule that aggravates inflammation, while under
11

treatment conditions such as cell therapy, they have shown to be anti-inflammatory
and more beneficial. The secondary role of MCP-1 is rarely looked at, and it could
potentially be involved in protective and regenerative features like neurogenesis,
angiogenesis, neuro-protection, etc., which we need to explore more deeply.

1.6 Objectives and Hypothesis
We hypothesize that MSCs directly and/or indirectly modulate the release of
MCP-1 through their interaction with pulmonary endothelial cells, and this
immunomodulatory effect is via, modification of the monocytes. The following aims
were designed to test this hypothesis:

Specific Aim 1: Under inflammatory conditions, the interaction between
pulmonary endothelial cells exposed to bone marrow-derived MSCs would
modify the release of trophic factors such as MCP-1.

Specific Aim 2: Interaction of bone marrow-derived MSCs and pulmonary ECs
after under inflammatory conditions modulates the monocyte mediated
immune response through MCP-1.

12

FIGURE 1. A schematic representation of the hypothesis. We hypothesize that
after an IV infusion of MSCs, a majority of the cells get trapped in the lungs. One of
the first cell type MSCs come in contact and interact with are the pulmonary
endothelial cells. This interaction modulates the release of the chemokine MCP-1.
This downstream then leads to the modulation of the immune response through the
modification of monocytes.

13

CHAPTER 2: MATERIALS AND METHODS

14

2.1 Isolation and culture of primary murine mesenchymal stromal cells
MSCs from fresh C57/BL6 mice (mMSCs) bone marrow aspirates were
prepared using their preferential attachment to tissue culture plastic as previously
described

54

. Briefly, bone marrow aspirate was obtained from the tibia and femoral

compartments. The aspirated marrow was then suspended in HBSS (Life
Technologies) and was filtered using a 70uM filter (Corning Life Sciences). The
filtered suspension was centrifuged at 1500 x g for 5 minutes. The pellet obtained
from this was immediately resuspended in complete culture medium consisting of
Dulbecco’s Modified Eagle’s Medium (DMEM) with high glucose and GlutaMAX
Supplement Pyruvate (Gibco), along with 20% fetal bovine serum (Atlanta
Biologics), 100 units/ml penicillin (Gibco) and 100ug/ml streptomycin (Gibco). Nonadherent cells were removed after 2 days. The adherent colonies were expanded
further till passage 3 to obtain pure colonies, and frozen at passage 3. The cells
were checked for typical spindle shape morphology and growth kinetics. The cells
were then thawed further and plated at 1 x 106 cells/ml and expanded further by
changing media every other day. When the cells reached 80% confluence, the
medium was discarded, and the cells were washed with phosphate-buffered saline
(PBS) (Life Technologies), and the adherent cells were harvested with 0.25%
trypsin/EDTA (Life Technologies) for 3 minutes at 37°C. Cells were used at
passages 4-5.

2.2 Primary murine pulmonary endothelial cells
Primary murine pulmonary endothelial cells (mPECs) were purchased from
Cell Biologics (Chicago, IL) at the third passage. The cells were expanded and
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grown in cell culture plates pre-coated with 0.2% gelatin (Sigma-Aldrich ) in
complete mouse endothelial cell media with growth factors (Cell Biologics, IL;
M1166). Cells were used at passage 4-5 for the subsequent experiment.

2.3 Isolation and verification of murine splenic immune cells and monocytes
Spleen tissue was isolated from C57/BL6 mice. The tissue was first
dissociated mechanically and then further enzymatically using 0.25% trypsin/EDTA
(Life Technologies) for 20-25 minutes at 37°C. The obtained splenocyte suspension
was filtered using a 70uM filter (Corning Life Sciences) with Hank’s balanced salt
solution (HBSS) (Life Technologies) and centrifuged at 1500 x g for 5 minutes. The
obtained cell pellet was used downstream for magnetic beads based isolation of two
cell population splenic immune cells CD11b+ cells and splenic monocytes CD115+
cells. CD11b+ cells were first isolated using the positive selection technique where
CD11b+ cells were magnetically labeled with CD11b MicroBeads conjugated to
monoclonal antibodies (Milltenyi Biotec, CA). The labeled cell suspension was
passed through MS Column (Miltenyi Biotec, CA), which was placed in a magnetic
field of a MACS Separator (Miltenyi Biotec, CA). The positively labeled CD11b+ cells
were retained in the column, the fraction of the unlabeled cells passed through the
column. The positively selected CD11b+ cells were flushed out after removing the
column from the magnetic field. The unlabeled cell fraction from the above step was
used to isolate CD115+ cells further. CD115+ cells were indirectly labeled with
CD115-biotin monoclonal antibodies and anti-biotin MicroBeads (Milltenyi Biotec,
CA). The downstream processing was similar to the one described above. The cell
fractions obtained from the above isolation processes yielded CD11b+ and CD115+
16

cells, respectively. Both CD11b+ and CD115+ cells were plated and used for
subsequent experiments.

2.4 Viability Assessment
mPECs, as well as mMSCs, were exposed to different concentrations of
recombinant mouse TNF-α and IFN-γ (R&D Systems) ranging from 500 nM to 0.5
nM. The cells were also exposed to recombinant mouse MCP-1 (R&D Systems) at
10ng/ml and mouse MCP-1 neutralizing antibody (R&D Systems) at 20ug/ml. At 24
hours of incubation, the viability of both mPECs and mMSCs was measured using
the colorimetric MTT assay (Promega Life Sciences). The viability was calculated as
a ratio based on the vehicle well, which was then converted to a percentage of
viable cells in comparison to the vehicle.
The viability of the primary mPECs and mMSCs was also measured every
time before the start of an experiment using the trypan blue staining assay. 0.4%
trypan blue solution (Gibco) was added at a 1:1 ratio to the cells, and the mixture
was loaded to the Countess Cell Counting Chamber slides (Invitrogen). These slides
were then read using the Countess II machine (Invitrogen), where the viability of the
cells was determined using the ratio between stained cells and the unstained cells.
The stained cells are the dead cells that are capable of taking up the trypan blue
dye, whereas the unstained cells are viable cells with intact cell membranes. The
viability of both the primary cells mPECs and mMSCs used in the experiments
remained > 90%.
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2.5 Immunofluorescence Staining
Immunofluorescence analysis was performed on the cultured mPECs to
confirm their endothelial origin. Briefly, the cells were plated in chamber slides at a
density of 60,000 cells. Once the cells were adherent, it was washed gently with
PBS and fixed with 4% paraformaldehyde solution (PFA) (Thermo Scientific) in PBS
for 20 minutes at room temperature. The fixed cells were then washed with PBS
three times for 5 minutes each. The samples were then blocked and permeabilized
with a solution of 0.1% Triton X-100 (Sigma-Aldrich) and 3% bovine serum albumin
(BSA) (Fisher Scientific) for 1 hour. The samples were rewashed with PBS three
times for 5 minutes, followed by their incubation with the Fluorescein labeled
Griffonia Simplicifolia Lectin I Isolectin B4 antibody (Vector Labs, Burlingame, CA;
FL-1201) in 3% BSA and 0.1% Triton-X solution overnight at 4ºC. The next morning
the samples were washed three times with PBS, 5 minutes each followed by DAPI
(Invitrogen) counter-stain for 5 minutes at room temperature. The samples were
rewashed with PBS three times, 5 minutes each, and stored in PBS at 4ºC until
imaging was done. The immunofluorescence images were acquired using the Zeiss
Axio Observer (Zeiss) microscope and ZEN Blue Edition Software (Zeiss).

2.6 Cytokine Chemokine Analysis using Enzyme-Linked Immunosorbent
Assay (ELISA)
Media of the various cell types used in these experiments, including mPECs,
mMSCs, co-cultures of mPECs and mMSCs, CD11b+ splenic immune cells, and
CD115+ splenic monocytes were analyzed for their secretome release using the
ELISA assays (BD Biosciences and R&D Systems). In this study, we analyzed the
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secretion levels of IL-1β, IL-1ra, VEGF (R&D Systems), MCP-1, and IL-6 (BD
Biosciences). Briefly, 96-well ELISA plates were coated with the appropriate capture
antibody and incubated overnight at room temperature (R&D Systems) or 4ºC (BD
Biosciences). The following morning the plates were washed three times using the
appropriate wash buffer and blocked using a solution of PBS with either 1% BSA
(R&D Systems) or 10% FBS (BD Biosciences) for an hour at room temperature.
Following this, the plates were washed three times and were now ready for the
addition of the appropriate samples and standards. The samples and standards
were incubated for two hours at room temperature. After two hours, the plates were
washed 3-5 times and were ready to be incubated with the detection antibody for 1
hour (BD Biosciences) or 2 hours (R&D Systems) at room temperature. Following
this, the plates were washed 3-7 times and were finally incubated with the
appropriate HRP conjugated enzyme substrate for 20 minutes. The plates were
washed

three

times,

and

the

substrate

solution

mixture

containing

tetramethylbenzidine and hydrogen peroxide, at a 1:1 ratio, were added to the
plates. Plates were let to develop at room temperature in the dark for 20-30 minutes,
and the reaction was stopped using a stop solution of 2N sulfuric acid. The
concentrations of the different cytokines were read at an absorbance of 450 nm and
were obtained using the FLUOstar optima microplate reader. .

2.7 Statistical Analysis
Significance between control and test groups was determined using the
paired two-tailed t-test. Data were considered to be statistically significant if P-value
< 0.05. Mean values were reported along with the standard error of the mean (SEM).
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CHAPTER 3: RESULTS
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3.1 Primary Murine Pulmonary Endothelial Cell Characterization
Murine pulmonary endothelial cells express α-galactose sugar residues that
are present on the cell surface. Griffonia Simplicifolia Lectin I Isolectin B4 is a useful
marker for non-primate endothelial cells that recognizes these residues. We
confirmed the biomarker phenotype of our primary murine endothelial cells by
staining with Griffonia Simplicifolia Lectin I Isolectin B4 antibody and fluorescence
analysis (Figure 2). The staining patterns were consistent with that of a pure murine
endothelial cell population.

(A)

(B)

(C)

FIGURE 2. Primary murine pulmonary endothelial cell characterization. Primary
murine pulmonary endothelial cells were characterized using Griffonia Simplicifolia
Lectin I Isolectin B4 antibody using immunofluorescence analysis. (A) Isolectin B4
stained primary murine endothelial cells at passage 5. (B) Nuclear staining of DAPI.
(C) Merged image of Isolectin B4 and DAPI staining.
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3.2 Cell Viability
Primary mMSCs at passage 5 in culture were subjected to a combination of
IFN-γ and TNF-α ranging from 500 nM to 0.5 nM in concentrations. The cells were
also subjected to recombinant MCP-1 (10ng/ml) and anti-MCP-1 neutralizing
antibody (20ug/ml) individually. The viability of the cells was calculated by comparing
the percentage change in cells vs. the vehicle. There was no significant change in
the overall viability of primary mMSCs at 24 hours after exposure to various
conditions tested in this experiment (Figure 3 A). The changes in the viability of
primary mPECs at passage 5 were also measured after exposure to the different
conditions as compared to the vehicle. Cells exposed to recombinant MCP-1
(10ng/ml) had a significantly increased viability percentage – significantly increasing
their proliferation rate – compared to the vehicle group, while the rest of the
conditions had no significant change in the overall viability of the mPECs (Figure 3
B).
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(50nM) +
Anti MCP-1 Ab
(20ug/ml)

FIGURE 3. Cell Viability of primary mMSCs and mPECs. Passage 5 primary
mMSCs and mPECs in culture were subjected to the following conditions: to a
combination of IFN-γ and TNF-α ranging from 500 nM to 0.5 nM, to recombinant
MCP-1 (10ng/ml) and to anti-MCP-1 neutralizing antibody (20ug/ml). mPECs
exposed to recombinant MCP-1 (10ng/ml) had a significant increase in viability
compared to the vehicle. The other conditions did not show any significant difference
in viability for both (A) mMSCs and (B) mPECs.

3.3 MCP-1 Secretion Levels Increase Under Inflammatory Conditions
We subjected mPECs in culture to a combination of IFN-γ and TNF-α,
inflammatory stimuli, ranging from 500 nM to 0.5 nM concentrations for 24 hours.
Following this, the inflammatory stimuli were removed and the cells were divided into
two groups: the control group (mPECs only) and the group exposed to mMSCs
(mPECs + mMSCs). 24 hours after mMSCs exposure, we collected the media and
23

measured the release of MCP-1 from the two groups (Figure 4 A). We found that
MCP-1 release in the mPECs only group had significantly increased across the
entire range of inflammatory concentrations tested (Figure 4 B). Similarly, the group
exposed to mMSCs (mPECs + mMSCs) also had a significant increase in MCP-1
release across the entire range of inflammatory concentrations tested (Figure 4 C).
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FIGURE 4. Inflammation Increases MCP-1 secretion. (A) Schematic of exposing
mPECs to various ranges of IFN-γ and TNF-α inflammatory stimuli and co-culturing
with mMSCs and measuring the release of MCP-1. (B) MCP-1 release from mPECs
(mPECs only) was significantly increased across all concentrations of IFN-γ and
TNF-α. (C) MCP-1 release in mPECs treated with mMSCs (mPECs + mMSCs) had
significantly increased across all concentrations of IFN-γ and TNF-α. Significant pvalue are denoted with asterisk (*), with p-value <0.05 considered as significant.

3.4 MCP-1 Released by Inflammation Modulates Secretome Release
As we had shown earlier MCP-1 release is modulated under inflammatory
conditions. We further wanted to see if over stimulation of MCP-1 or neutralization of
MCP-1 changes the secretome release in co-cultures of mPECs and mMSCs. We
subjected the co-cultures of mPECs and mMSCs in culture to three conditions: 1)
Control, 2) Over Stimulation of MCP-1 with recombinant MCP-1 (Recomb MCP-1) at
10ng/ml concentration and 3) Neutralization of MCP-1 with anti MCP-1 neutralizing
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antibody (Anti MCP-1 Ab) at 20ug/ml concentration for 24 hours. Following this we
collected the media (Old Media) and added fresh media with no stimuli present. 24
hours later, the media (Fresh Media) was collected (Figure 5 A). We showed that
MCP-1 was effectively neutralized in the presence of the Anti MCP-1 Ab and was
significantly higher in the presence recombinant MCP-1 (Figure 5 B (i)). We found
that, in the Old Media, VEGF release was significantly reduced when MCP-1 was
over stimulated using Recombinant MCP-1 protein and when MCP-1 was effectively
neutralized with anti MCP-1 neutralizing antibody (Figure 5 B (v)). There were no
significant changes in the release of IL-1β, IL-1ra and IL-6 (Figure 5 B (ii), (iii) and
(iv)). After the stimuli were removed (Fresh Media), MCP-1 levels had bounced back
(Figure 5 C (i)). We found that IL-1ra secretion levels, in the Fresh Media, had
significantly reduced in the group where MCP-1 was previously neutralized (Figure 5
C (ii)). We also found that IL-6 secretion levels had significantly increased in the
previously neutralized MCP-1 group (Figure 5 C (iii)). We were unable to detect the
presence of IL-1β or VEGF in the fresh media.
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FIGURE 5. MCP-1 modulates secretome release profile. (A) Schematic of
exposing co-cultures of mPECs and mMSCs to over stimulation of MCP-1 (Recomb
MCP-1) or neutralization of MCP-1 (Anti MCP-1 Ab). (B) Old Media: (i) MCP-1 was
effectively neutralized in the presence of Anti MCP-1 Ab. (ii) - (iv) The release of IL1β, IL-1ra and IL-6 had no significant difference, respectively. (v) In the presence of
Recomb MCP-1 and Anti MCP-1 Ab VEGF secretion had significantly reduced. (C)
Fresh Media: (i) After the stimuli were removed, MCP-1 release bounced back. (ii)
IL-1ra release, however, was significantly reduced in the groups were MCP-1 was
previously neutralized. (iii) The release of IL-6 had significantly increased in the
group that had MCP-1 previously neutralized. IL-1β and VEGF presence were not
detectable in the fresh media. Significant p-value are denoted with asterisk (*), with
p-value <0.05 considered as significant.
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3.5 Secretome Release Profile of mPECs and co-cultures of mPECs and
mMSCs changes after neutralization of MCP-1 in inflammation
We subjected mPECs (mPECs Only) and co-cultures of mPECs and mMSCs
(mPECs + mMSCs) in culture to three conditions: 1) Control, 2) Inflammatory Stimuli
IFN-γ and TNF-α at 50nM concentration (TNF-α + IFN-γ), and 3) Inflammatory
stimuli IFN-γ and TNF-α at 50nM concentration + Anti MCP-1 neutralizing antibody
(Anti MCP-1 Ab) at 20ug/ml for 24 hours. Following this we removed the media and
added fresh media with only anti MCP-1 neutralizing antibody present in the
appropriate groups. Downstream, this media was also used as conditioned media
(CM) in splenic monocytes experiment. 24 hours later, the media (Fresh Media) was
collected (Figure 6 A).
In the Fresh Media from mPECs, MCP-1 is neutralized in the presence of Anti
MCP-1 Ab (Figure 6 B (i)). The release of IL-6 levels had significantly increased
when mPECs group that was previously exposed to inflammatory stimuli and in the
group when MCP-1 was neutralized. (Figure 6 B (iv)). There was no significant
difference in the release of IL-1β, IL-1ra, and VEGF from mPECs (Figure 6 B (ii), (iii),
and (v)).
The Fresh Media in the presence of mMSCs (mPECs + mMSCs group), had
neutralization of MCP-1 with Anti MCP-1 Ab (Figure 6 C (i)). We also found a
significant increase in the release of IL-6 and VEGF in the Fresh Media of mPECs +
mMSCs group, that was previously treated with the inflammatory stimuli (Figure 6 C
(iv) and (v)). Although in the Fresh Media, we saw that in the presence of mMSCs
(mPECs + mMSCs group) there was an increase in the secretion of IL-6 and VEGF,
when MCP-1 was neutralized, it was not statistically significant (Figure 6 C (iv) and
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(v)). There was no significant difference in the release of IL-1β and IL-1ra from any
of the groups (Figure 6 C (ii) and (iii)).
Logarithmic Fold change data was used to appropriately compare the
secretome release between mPECs only groups and mPECs + mMSCs groups. In
the fresh media, IL-1β had a reduced logarithmic fold change difference in the
mMSCs treated group in the presence of MCP-1 neutralizing antibody (Figure 6 D
(ii)). We also observed that in the fresh media there was an increased logarithmic
fold change difference in the secretion of IL-6 and VEGF release in groups treated
with mMSCs that was previously exposed to inflammatory stimuli (Figure 6 D (iv),
and (v)). There was no significant logarithmic fold change difference observed in the
secretion of IL-1ra in any of the groups (Figure 6 D (iii)).
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FIGURE 6. Changes in Secretome Release of mPECs and co-cultures of
mPECs and mMSCs Previously Exposed to Inflammatory Stimuli. (A)
Schematic of exposing mPECs or co-cultures of mPECs and mMSCs to
inflammatory stimuli (TNF-α and IFN-γ (50 nM)) or inflammatory stimuli + MCP-1
neutralizing antibody (Anti MCP-1 Ab (20ug/ml)). (B) mPECs Only: (i) In the
presence of MCP-1 neutralizing antibody, MCP-1 secretion appears to be
neutralized. (ii), (iii) and (v) The release of IL-1β, IL-1ra and VEGF had no significant
difference, respectively. (iv) IL-6 secretion levels were elevated in the groups
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previously exposed to inflammatory stimuli and also in the presence of MCP-1
neutralizing antibody. (C) mPECs + mMSCs: (i) In the presence of MCP-1
neutralizing antibody, MCP-1 secretion appears to be neutralized. (ii) and (iii) There
was no significant difference in the release of IL-1β and IL-1ra, respectively (iv) and
(v) IL-6 and VEGF secretion were increased in cells that were previously exposed to
the inflammatory stimuli. (D) Logarithmic Fold change data was used to
appropriately compare the secretome release between mPECs only groups and
mPECs + mMSCs groups. (i) Logarithmic Fold Change of MCP-1 secretion. (ii)
Logarithmic fold change of IL-1β secretion levels were significantly reduced in the
mMSCs treated group in the presence of MCP-1 neutralizing antibody. (iii) There
was no significant change observed in the logarithmic fold change in the secretion of
IL-1ra. (iv) and (v) There was increase in the logarithmic fold change difference in
the secretion of IL-6 and VEGF in the mMSCs treated groups that were previously
exposed to the inflammatory stimuli. Significant p-value are denoted with asterisk (*),
with p-value <0.05 considered as significant.

3.6 MCP-1’s Modulation of the Secretome Release Response of Splenic
Immune Cells and Monocytes
We subjected splenic immune cells CD11b+ cells and splenic monocytes
CD115+ cells in culture to six conditions 1) CM from mPECs only group, 2) CM from
mPECs previously exposed to inflammatory stimuli (IFN-γ and TNF-α (50nM)), 3)
CM from mPECs exposed to MCP-1 neutralizing antibody (Anti MCP-1 Ab), 4) CM
from mPECs + mMSCs group 5) CM from mPECs + mMSCs previously exposed to
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inflammatory stimuli (IFN-γ and TNF-α (50nM)), and 6) CM from mPECs exposed to
MCP-1 neutralizing antibody (Anti MCP-1 Ab) (Figure 7. A).
In the CD11b+ Fresh Media, the results were similar to that of the CD11b+ Old
Media groups. No significant differences in the release of IL-1β and VEGF were
observed in the groups previously treated with conditioned media from mPECs only
(Figure 7. B (i) and (ii) and Figure 7. C (i) and (ii)). IL-1ra release was observed to
reduced in the group that was previously treated with mMSCs and MCP-1
neutralizing antibody. MCP-1 and IL-6 secretion were not detected in the Fresh
Media. Logarithmic fold change data was used to appropriately compare the
secretome release between CD11b+ groups previously treated with CM from mPECs
only and CM from mPECs + mMSCs groups. There were no significant logarithmic
fold change differences observed in the release of IL-1β, IL-1ra and VEGF in any of
the groups (Figure 7. D (i) – (iii)).
The secretome release of CD115+ cells in Fresh Media we observed no
significant differences in the release of IL-1β or VEGF any of the groups (Figure 8. A
(i) – (ii) and Figure 8. B (i) – (ii)). MCP-1 release was not detected in Fresh Media.
Logarithmic fold change data was used to appropriately compare the secretome
release between CD115+ groups previously treated with CM from mPECs only and
CM from mPECs + mMSCs groups. There were no significant logarithmic fold
change differences in the release of IL-1β and VEGF in any of the groups (Figure 8.
C (i) – (ii)).
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FIGURE 7. Changes in Secretome Release of CD11b+ Splenic immune cells.
(A) Schematic of exposing CD 11b+ immune cells to CM media collected from the
previous experiment where mPECs or co-cultures of mPECs and mMSCs were
exposed to inflammatory stimuli (TNF-α and IFN-γ (50 nM) Anti MCP-1 Neutralizing
Antibody. (B) CD11b+ exposed to CM from mPECs only: (i) – (iii) There was no
significant difference in the release of IL-1β, IL-1ra and VEGF, respectively. (C)
CD11b+ exposed to CM from mPECs and mMSCs: (i) and (iii) There was no
significant difference in the release of IL-1β and VEGF, respectively. (ii) IL-1ra
release was reduced in the group were MCP-1 was previously neutralized. (D)
Logarithmic fold change data was used to appropriately compare the secretome
release between CD11b+ cells previously treated with CM from mPECs only groups
and mPECs + mMSCs groups. (i) – (iii) There was no significant logarithmic fold
change differences observed in the release of IL-1β, IL-1ra, and VEGF, respectively.
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Significant p-value are denoted with asterisk (*), with p-value <0.05 considered as
significant.
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FIGURE 8. Changes in Secretome Release of CD115+ splenic monocytes.
(A) CD115+ exposed to CM from mPECs only: (i) – (ii) There was no significant
difference in the release of IL-1β and VEGF, respectively (B) CD115+ exposed to
CM from mPECs and mMSCs: (i) – (ii) There was no significant difference in the
release of IL-1β and VEGF, respectively (C) Logarithmic fold change data was used
to appropriately compare the secretome release between CD115+ cells previously
treated with CM from mPECs only groups and mPECs + mMSCs groups. (i) – (ii)
There was no significant logarithmic fold change differences observed in the release
of IL-1β and VEGF, respectively. Significant p-value are denoted with asterisk (*),
with p-value <0.05 considered as significant.
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CHAPTER 4 DISCUSSION AND FUTURE DIRECTIONS
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Stroke is a leading cause of serious long-term disability in the world. Cellbased therapies such as MSCs therapy have increasingly shown great promise for
ischemic stroke recovery, with some therapies already in various stages of clinical
trials. Although a majority of the IV administered MSCs lodge in the lungs, studies
still observed an endogenous restorative effect in the brain, either the release of
trophic factors or through immunomodulation

8, 9, 13, 16, 37

. During this ‘Pulmonary

First Pass’, the MSCs mainly interact with the pulmonary microvascular endothelial
cells

37

. Many studies have previously shown that MCP-1 plays a critical role in

immune modulation under inflammatory conditions 43-45.
In this study, we aimed to look at the interaction between mPECs and
mMSCs under inflammatory conditions, similar to the stroke milieu. We specifically
focused on the secretome release after this interaction, including MCP-1 release.
We found that under inflammatory conditions, MCP-1 release increases in mPECs
and co-cultures of mPECs and mMSCs. Previous studies have shown that MCP-1
release in increased during inflammatory events

47, 55-58

. However, many studies

seldom look at the release modulation of MCP-1 in the presence of stem cells, like
MSCs.
In this study, we also looked at how secretome release was affected, when
co-cultures of mPECs and mMSCs were either over-stimulated with recombinant
MCP-1 protein or neutralization of the secreted MCP-1 using a neutralization
antibody. We observed when MCP-1 was effectively neutralized, the secretome
release of VEGF had significantly decreased. VEGF is a trophic factor that acts as a
potent pro-angiogenic and promotes neovascularization

59-61

. Many studies have

shown that after MSC treatment, the secretion of VEGF increases
44

61-63

. In our study,

we observed that MCP-1 plays a role in modulating the release of VEGF, through
the interaction of mPECs and mMSCs. A study by Jay, SM., 2010,

64

showed that

MCP-1 and VEGF together play an important role in supporting the survival of
transplanted endothelial cells, while also increasing the formation of functional
vessels from the transplanted endothelial cells

64

. Some studies have also shown

that MCP-1 by itself can modulate angiogenesis under certain conditions 65-67.
In the same experiment, we also observed the release modulation of the proinflammatory cytokine IL-1β, under certain conditions. The presence of MSCs is
more than likely causing these observed changes in the secretome release. Studies
have shown that after MSC therapy, IL-1β expression and secretion goes down 68-70.
Studies previously suggested that MCP-1 plays a detrimental role under
inflammatory conditions. In MCAo animal stroke models, MCP-1 has been shown to
increase and infarct size and volume, mainly through the role it plays in the
recruitment of inflammatory monocytes and macrophages

71

. Studies have also

shown that infarct size was much smaller in animals that had MCP-1 expression
knocked down

48

. While this might be true in inflammatory conditions, after

administering treatments like cell therapy, the role that MCP-1 plays could be
altered. Studies over the past few years have started revealing the importance of
MCP-1 in the migration of various stem cells. Stem cells such as NSCs, MSCs,
dental pulp derived MSCs, etc., were shown to migrate better and home to regions
of insult or injury in the presence of MCP-1 50-52, 72-74.
In our study, we wanted to see under therapeutic conditions how MCP-1
produced

after

the

interaction

between

pulmonary

endothelial

cells

and

mesenchymal stem cells change secretome release following inflammation. We
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observed that when MCP-1 was neutralized, there was an increased expression of
IL-6 levels, which was an interesting observation. IL-6 has been long associated as
a pro-inflammatory cytokine and had been associated with detrimental outcomes in
a disease condition

75, 76

. More recent studies are showing that IL-6 plays a dual role

and is also capable of acting as an anti-inflammatory factor. The anti-inflammatory
response of IL-6 is carried out through its interaction with membrane-bound IL-6
receptor in classical signaling. Whereas, the pro-inflammatory activity is in response
to trans-signaling, where IL-6 interacts with soluble IL-6 receptor

77

. Similar to MCP-

1, IL-6 is also involved in the recruitment of leukocytes. It has been shown that
animals that were knockdown of IL-6 exhibited poor recruitment of leukocytes. They
also found that the interaction between IL-6 and endothelial cells through the soluble
IL-6 receptor plays a central role in the leukocyte recruitment 78.
Many studies previously have looked at the roles of IL-6 and MCP-1
independently. However, results from our study indicate there might be a codependent relationship between the two trophic factors. A recent study by Hosaka,
K., et al., 201779, has also shown that the interplay between IL-6 and MCP-1 plays a
vital role in intra-aneurysmal tissue healing
downstream mediator of MCP-1

79

79

. They suggest that IL-6 is a

. A few other studies have also shown a co-

dependent relationship between these two trophic factors 80, 81.
Another important aim of this study was to look at MCP-1’s (released after the
interaction of PECs and MSCs) immunomodulatory role on the differential
recruitment of monocytes. In our study, we were not able to find any significant
differences in the secretome release of the monocytes, when they interacted with
the conditioned media. One main reason for this could have been the minimal
46

number of monocytes that we were able to isolate from the splenic tissue. Reports
say that there are only about 3.5-5% of splenic cells that are monocytes.
A few studies have reported that following MSC treatment, monocyte and
macrophages polarize towards an anti-inflammatory M2 subtype

70, 82

. Cancer

studies, however, in recent years, have provided more evidence to support the
MCP-1 plays an essential role in this M2 type polarization. A recent study by Su, W.,
et al., 2019

83

, showed that in tumor microenvironments, MCP-1 plays an important

role in recruiting tumor-associated macrophages and polarizing them to an M2
phenotype. This is achieved through the interaction it has with the tumor stem cells
83

. Studies have shown that MCP-1 promotes angiogenesis and M2 polarization of

macrophages in tumor conditions

84, 85

. Studies have also shown the role of IL-6 in

the recruitment of M2 polarized macrophages in conditions such as cancer and
obesity

86, 87

. As previously mentioned, IL-6 and MCP-1 seem to have a co-

dependent relationship. Cancer studies have also explored this and have shown that
MCP-1, along with IL-6, has an increased expression in tumor microenvironments.
This increased expression helps in the protection of the tumor-recruited monocytes,
while at the same time aiding in their differentiation towards the M2 phenotype

88

.

While these conditions might be detrimental in a cancer setting, they could be
beneficial in stroke.
Although this study tried to elucidate how MCP-1 released through the
interaction of pulmonary endothelial cells and mesenchymal stem cells modulates its
immunomodulatory effects through monocytes, the results were inconclusive. All the
experiments conducted for this study were done in an in-vitro setting. Although this
could give us a preliminary idea of what’s going on, to get more precise answers, we
47

would have to move to an in-vivo setting. Secondly, a major limitation we had, as
mentioned above, was the limited number of splenic monocytes that we were able to
isolate. To overcome this issue, we could move towards the collection of monocytes
from other sources such as bone marrow and peripheral blood, while also examining
the tissue macrophages and the effects on them. In an in-vivo setting, we can better
attain stroke-like conditions, and further explore if any of the changes seen through
the interaction of PECs and MSCs affect different types of brain cells, especially the
resident microglial population. To get a better understanding of the IL-6 and MCP-1
co-dependent relationship, we would include experiments where we block both and
see what outcome we get. Further experiments will also be required to understand
the exact mechanism behind these observations.
In conclusion, our study was able to elucidate that MCP-1 release under
stroke like conditions was modulated through the interaction of PECs and MSCs.
However, our study was unable to explain MCP-1’s role in immunomodulation
through monocytes.
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